The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 331:609-610 September 1, 1994 Number 9
NextNext

Therapy for ß-Thalassemia -- A Paradigm for the Treatment of Genetic Disorders

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
{beta}-Thalassemia is one of the most common single-gene disorders. More than 100 mutations in or around the {beta}-globin gene are known to cause decreased production of {beta}-globin, which in turn leads to the excess accumulation of unstable {alpha}-globin chains, ineffective erythropoiesis, and shortened red-cell survival. Although the clinical severity of {beta}-thalassemia varies considerably, most patients who are homozygous for {beta}-thalassemia become dependent on transfusions and thus have the transfusion-related complications of iron overload, alloimmunization, and viral infection. Recent advances in basic and clinical research offer the clinician not only new approaches to the treatment of these patients but also the . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.